BD (Becton, Dickinson and Company) announced new reporting capabilities for COVID-19 data, enabling scheduled reports to be generated from BD Synapsys Informatics (version 3.84), according to a press release.
BD Synapsys Informatics is an optional integrated informatics solution available to customers using the BD Veritor Plus System, a portable instrument delivering SARS-CoV-2 antigen test results in approximately 15 minutes, and the BD MAX System, a molecular diagnostic platform returning results in two to three hours.
Both BD Veritor and BD MAX systems have been granted emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) to perform SARS-CoV-2 diagnostic testing.
The BD Synapsys solution's new capabilities allow global customers to create general-purpose reports with COVID-19 data from their BD Veritor and/or BD MAX systems. The solution also offers configured reporting capabilities, which allow customers in the U.S. to generate reports in accordance with the U.S. Coronavirus Aid, Relief, and Economic Security (CARES) Act. The CARES Act requires COVID-19 testing facilities to report testing data to local and federal health authorities daily, including the number of tests performed, results and key patient demographics. Additional configured reports can be developed, as needed.
Used with the BD Veritor Plus System and/or the BD Max System, the BD Synapsys Informatics 3.84 solution allows customers to export all SARS-CoV-2 test results in a single daily report.
BD Synapsys Informatics is the informatics platform for BD diagnostics systems. The solution provides secure connectivity, integrated workflows, and on-demand actionable insights for laboratories and facilities with Clinical Laboratory Improvement Amendments (CLIA) waivers.
